Measles-Rubella MAP Vaccine

This project aims to develop a measles and rubella (MR) vaccine loaded onto a novel microneedle array patch (MAP) delivery system. The stages funded through this grant include safety evaluation, immunogenicity, and efficacy of a novel MR-MAP in mice. This MR-MAP is designed to improve delivery efficiency, reduce wear time, and have greater antigen stability during storage. Vaccines delivered through MAPs have the potential to increase vaccine coverage, particularly in remote and underserved areas, by reducing the need for extensive cold chain networks and specially trained healthcare workers to administer vaccine doses. The MAP platform has potential applicability beyond MR and other lyophilized vaccines, such as mRNA vaccines.